Literature DB >> 28052308

Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer.

S Yamashita1, G Passot1, T A Aloia1, Y S Chun1, M Javle2, J E Lee1, J-N Vauthey1, C Conrad1.   

Abstract

BACKGROUND: The clinical significance of abnormally high levels of carbohydrate antigen (CA) 19-9 after resection of biliary tract cancer (BTC) is not well established. The aim of this study was to determine the prognostic value of CA19-9 normalization in patients undergoing resection of BTC with curative intent.
METHODS: Patients with BTC undergoing resection with curative intent (1996-2015) were divided into those with normal preoperative CA19-9 level (normal CA19-9 group), those with an abnormally high preoperative CA19-9 level (over 37 units/ml) and normal postoperative CA19-9 level (normalization group), and those with an abnormally high preoperative CA19-9 level and abnormally high postoperative CA19-9 level (non-normalization group). Overall survival (OS) was analysed and predictors of OS were determined.
RESULTS: The normal CA19-9 group (180 patients) and normalization group (74) had better OS than the non-normalization group (58) (3-year OS rate 70·4, 73 and 31 per cent respectively; both P < 0·001). The normal CA19-9 and normalization groups had equivalent OS (P = 0·880). On multivariable analysis, factors associated with worse OS were lymph node metastases (hazard ratio (HR) 1·78; P = 0·014) and abnormally high postoperative CA19-9 level (HR 3·16; P < 0·001). In the normalization group, OS did not differ after R0 versus R1 resection (3-year OS rate 69 versus 62 per cent respectively; P = 0·372); in the non-normalization group, patients with R1 resection had worse OS (3-year OS rate 36 and 20 per cent for R0 and R1 respectively; P = 0·032).
CONCLUSION: Non-normalization of CA19-9 level after resection of BTC with curative intent was associated with worse OS. R1 resection was associated with a particularly poor prognosis when CA19-9 levels did not normalize.
© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28052308     DOI: 10.1002/bjs.10415

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  18 in total

1.  Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for "Borderline Resectable" in the Field of Surgery for Hilar Cholangiocarcinoma.

Authors:  Ryusei Matsuyama; Daisuke Morioka; Ryutaro Mori; Yasuhiro Yabushita; Seigo Hiratani; Yohei Ota; Takafumi Kumamoto; Itaru Endo
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

2.  A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery.

Authors:  Feng Zhang; Keshu Hu; Bei Tang; Mengxin Tian; Shenxin Lu; Jia Yuan; Miao Li; Rongxin Chen; Zhenggang Ren; Yinghong Shi; Xin Yin
Journal:  J Gastrointest Surg       Date:  2020-04-29       Impact factor: 3.452

3.  Early Recurrence in Resected Gallbladder Carcinoma: Clinical Impact and Its Preoperative Predictive Score.

Authors:  Yuji Shimizu; Ryo Ashida; Teiichi Sugiura; Yukiyasu Okamura; Katsuhisa Ohgi; Mihoko Yamada; Shimpei Otsuka; Takeshi Aramaki; Akifumi Notsu; Katsuhiko Uesaka
Journal:  Ann Surg Oncol       Date:  2022-06-06       Impact factor: 4.339

Review 4.  Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives.

Authors:  Alessandro Rizzo; Angela Dalia Ricci; Simona Tavolari; Giovanni Brandi
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

5.  The Prognostic Value of the CA19-9/TBIL Ratio in Patients with Biliary Tract Cancers (BTCs): A Retrospective Study.

Authors:  Jianchun Xiao; Li Wang; Tao Hong; Binglu Li; Wei Liu; Qiang Qu; Chaoji Zheng; Xiaodong He
Journal:  J Oncol       Date:  2021-02-23       Impact factor: 4.375

6.  Systemic inflammation score predicts survival in patients with intrahepatic cholangiocarcinoma undergoing curative resection.

Authors:  Yong Zhang; Shi-Ming Shi; Hua Yang; Liu-Xiao Yang; Zheng Wang; Xue-Dong Li; Dan Yin; Ying-Hong Shi; Ya Cao; Zhi Dai; Jian Zhou; Qing Chen
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

7.  Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma.

Authors:  Tianyi Fang; Hao Wang; Yunfu Cui; Zhidong Wang; Yufu Wang; Xuan Lin
Journal:  Dis Markers       Date:  2019-02-04       Impact factor: 3.464

8.  The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer.

Authors:  Yoji Miyahara; Shida Takashi; Yoshiaki Shimizu; Masayuki Ohtsuka
Journal:  World J Surg Oncol       Date:  2020-04-22       Impact factor: 2.754

9.  Preoperative Bilirubin-Adjusted Carbohydrate Antigen 19-9 as a Prognostic Factor for Extrahepatic Cholangiocarcinoma Patients at a Single Center.

Authors:  Jiayi Li; Qiao Chen; Bao Jin; Yue Shi; Xiangan Wu; Haifeng Xu; Yongchang Zheng; Yingyi Wang; Shunda Du; Xin Lu; Yilei Mao; Xinting Sang
Journal:  Cancer Manag Res       Date:  2020-01-20       Impact factor: 3.989

10.  Development and Validation of a Nomogram for Predicting Survival in Gallbladder Cancer Patients With Recurrence After Surgery.

Authors:  Mingyu Chen; Shijie Li; Win Topatana; Xiaozhong Lv; Jiasheng Cao; Jiahao Hu; Jian Lin; Sarun Juengpanich; Jiliang Shen; Xiujun Cai
Journal:  Front Oncol       Date:  2021-01-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.